StemCell Therapy

Closing Date: 19/12/2022Location: Manchester

An exciting opportunity has arisen at The Christie Pathology Partnership (CPP) for a Band 7 Clinical Cytogeneticist to join our Cytogenetics department. Clinical Cytogeneticist will work as part of a team to provide an effective and high-quality genomic analysis service to aid the diagnosis and treatment of patients with leukaemia and other cancers for Greater Manchester, the North West of England and other customers of the Christie Pathology Partnership. About us The Christie Pathology Partnership was formed in 2014 and is a joint venture between The Christie NHS Foundation Trust and SYNLAB, the largest provider of laboratory pathology and diagnostic services in Europe. We provide Pathology services for The Christie, the largest single site cancer centre in Europe, treating more than 44,000 patients a year and recently rated Outstanding by the CQC. SYNLAB is the European leader in delivery of high quality pathology testing and imaging services. SYNLAB operates in 35 countries across four continents, employing more than 20,000 members of staff and conducting approximately 500 million tests per annum. SYNLAB in the UK is a trusted expert in clinical laboratory services, drug and alcohol testing and food testing. We provide a wide range of testing capabilities and advanced pathology services through to the most innovative molecular and genetic diagnostic tests available today. The purpose of the role is to: To apply specialist scientific knowledge in cancer cytogenomics in the interpretation and reporting of, often complex, genetic information to clinicians and in producing interpretive reports for authorisation by a senior Clinical Cytogeneticist. To participate in laboratory and quality management processes to ensure the effective operation of the department and to maintain the service to standards expected by local policies, professional guidelines and UKAS accreditation, include writing and reviewing SOPs, participation in internal audit and external EQA. The post holder will participate on a rotational basis specific duties covering; duty scientist role including effective specimen handling, interpretation of referral reasons, deciding test and culture regimes, allocation of duties and dealing with telephone enquiries; managing FISH workflow on both liquid and FFPE preparations. The postholder will supervise and provide scientific support to technical staff. The role will involve contributing to the diagnostic workload for G-band chromosome analysis of blood and bone marrow preparations. To participate in SNP array analysis and interpretation, as part of a new service currently in development in the department. The post holder will have specific designated departmental responsibilities, appropriate to the grade of post, allocated according to training and experience. These will be directed by the Service Managers and may be on a rotational basis. Develop personal knowledge of genomics for the benefit of the service and the wider scientific community. The successful candidate will ideally have: A minimum of second class BSc(Hons) in a relevant subject. State registration with Health and Care Professions Council as a Clinical Scientist. Post Graduate Certificate of Competence in Clinical Cytogenetics or equivalent. Formal training as a Clinical Scientist in diagnostic Clinical Cytogenetics including work with chromosome analysis and FISH. High level working knowledge of Cytogenetic techniques including fine laboratory work, sterile culture work, sample preparation and microscopy requiring manual dexterity. Highly skilled in cytogenomic analysis techniques, such as G-banded chromosome analysis, FISH analysis and SNP arrays. We SYNLAB is a committed equal opportunities employer and we are open to flexible working. Once trained, the successful candidate may be expected to cover early evening and weekend sample receipt. We will accept applications from trainee scientists who are nearing registration. Applicants must currently have permission to work in the UK. For further information please email: asmaa.tanver@synlab.co.uk

Asmaa TanverEmail: asmaa.tanver@synlab.co.ukWebsite: https://synlab.co.uk/careers/opportunities/

Read the original:
BSGM - The British Society for Genetic Medicine

What is an eye emergency?

An eye emergency occurs any time you have a foreign object or chemicals in your eye, or when an injury or burn affects your eye area.

Remember, you should seek medical attention if you ever experience swelling, redness, or pain in your eyes. Without proper treatment, eye damage can lead to partial loss of vision or even permanent blindness.

Eye emergencies cover a range of incidents and conditions, each with their own distinct symptoms.

You should contact your doctor if it feels like you have something in your eye, or if you experience any of the following symptoms:

If theres an injury to your eye, or if you have sudden vision loss, swelling, bleeding, or pain in your eye, visit an emergency room or urgent care center.

Serious complications can occur from an eye injury. You shouldnt attempt to treat yourself. Although you may be tempted, be sure not to:

If you wear contact lenses, dont take them out if you think youve suffered an eye injury. Attempting to remove your contacts can make your injury worse.

The only exceptions to this rule are in situations where you have a chemical injury and your lenses didnt flush out with water, or where you cannot receive immediate medical help.

The best thing you can do in an eye emergency is to get to your doctor as soon as possible.

Chemical burns result when cleaning products, garden chemicals, or industrial chemicals get into your eyes. You can also suffer burns in your eye from aerosols and fumes.

If you get acid in your eye, early treatment generally results in a good prognosis. However, alkaline products like drain cleaners, sodium hydroxide, lye, or lime can permanently damage your cornea.

If you get chemicals in your eye, you should take the following steps:

If something gets in your eye, it can cause eye damage or a loss of vision. Even something as small as sand or dust can cause irritation.

Take the following steps if you have something small in your eye or eyelid:

Glass, metal, or objects that enter your eye at high speed can cause serious damage. If something is stuck in your eye, leave it where it is.

Do not touch it, do not apply pressure, and do not attempt to remove it.

This is a medical emergency and you should seek help immediately. Try to move your eye as little as possible while you wait for medical care. If the object is small and youre with another person, it may help to cover both eyes with a clean piece of cloth. This will reduce your eye movement until your doctor examines you.

If you have a cut or scratch to your eyeball or eyelid, you need urgent medical care. You may apply a loose bandage while you wait for medical treatment, but be careful not to apply pressure.

You usually get a black eye when something hits your eye or the area surrounding it. Bleeding under the skin causes the discoloration associated with a black eye.

Typically, a black eye will appear as black and blue and then turn purple, green, and yellow over the next few days. Your eye should return to normal coloring within a week or two. Black eyes are sometimes accompanied by swelling.

A blow to the eye can potentially damage the inside of the eye so its a good idea to see your eye doctor if you have a black eye.

A black eye can also be caused by a skull fracture. If your black eye is accompanied by other symptoms, you should seek medical care.

Eye injuries can happen anywhere, including at home, work, athletic events, or on the playground. Accidents can happen during high-risk activities, but also in places where you least expect them.

There are things you can do to decrease your risk of eye injuries, including:

To decrease your chances of developing permanent eye damage, you should always see an eye doctor after you experience an eye injury.

View post:
Eye Emergencies: Types, Symptoms, and Prevention - Healthline

Visual acuity is measured using the Snellen scale. A Snellen test usually consists of several rows of letters which get smaller as you read down the chart.

On the Snellen scale, normal visual acuity is called 6 / 6, which corresponds to the bottom or second bottom line of the chart. If you can only read the top line of the chart, then this would be written as 6 / 60. This means you can see at 6 metres what someone with standard vision could see from 60 metres away.

The figures 6 / 60 or 3 / 60 are how the result of a Snellen test are written. The first number given is the distance in metres from the chart you sit when you read it. Usually this is a 6 (for 6 metres) but would be 3 if you were to sit closer to the chart (3 metres away).

The second number corresponds to the number of lines that you can read on the chart. The biggest letters, on the top line, correspond to 60. As you read down the chart, this number gets smaller as it corresponds to the lines with smaller letters. Someone with standard vision can read towards the bottom of the chart. Standard vision can be referred to 6 / 6 vision.

For example, if the second line of the chart was marked as the 36 line, a person with standard vision (6 / 6) would be able to read this line on the chart when it was 36 metres away. However, if you had a Snellen score of 6 / 36, you would only be able to read the same line at 6 metres away. In other words, you need to be much closer to the chart to be able to read it. Generally, the larger the second number is, the worse your sight is.

Follow this link:
The criteria for certification | RNIB

Foresight: Eye-Net Successfully Showcases its Advanced Solution to Leading OEMs and Tier One Suppliers in Japan  Marketscreener.com

Read this article:
Foresight: Eye-Net Successfully Showcases its Advanced Solution to Leading OEMs and Tier One Suppliers in Japan - Marketscreener.com

VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence.

Go here to read the rest:
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya management will participate in the Piper Sandler 34th Annual Healthcare Conference, taking place in New York, NY, from November 29th to December 1st.

Read the original post:
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time.

Read more:
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

Link:
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology entitled “Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects”(1) . The study was completed by researchers at the Brigham and Womens Hospital (BWH) and Harvard Medical School. The goal of the study was to assess safety and the immune effects of an entirely human, previously uncharacterized nasal anti-CD3 mAb (foralumab) in humans and its in vitro stimulatory properties. The findings support Tiziana’s intranasal foralumab platform as a new modality for the treatment of autoimmune and CNS diseases.

Here is the original post:
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell...

Secures Revocation of Patent for Peptide Inhibitor of Plasma Kallikrein (PKal)

See the article here:
Oxurion Further Improves THR-149 Patent Position

NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11

Read the rest here:
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise --VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas’ engagement with Bright Minds as Chief Medical Officer has been terminated.

Read the original:
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

Additional production runs and increased processing for the benefit of patients Additional production runs and increased processing for the benefit of patients

Read more:
Curium’s Customers to Benefit From Mo-99 Production Restart

KRAKOW, Poland, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE:RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced third quarter 2022 financial results and provided a corporate update.

Original post:
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company Announcement

Read the rest here:
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

Continued here:
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below:

Read more here:
Eyenovia to Present at Upcoming BTIG Ophthalmology Day

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler’s 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs. One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.

Read the rest here:
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper...

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 30 consecutive business days. The notification letter does not result in the immediate delisting of the Company’s Ordinary Shares and has no current immediate effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.

Continued here:
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the "Board" or "Directors"), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company’s Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.

Read the original post:
OKYO Pharma Limited – PDMR dealing